(HealthDay)—Incretin treatment appears to improve non-ST-elevation myocardial infarction (NSTEMI) outcomes in patients with type 2 diabetes and non-obstructive coronary artery stenosis (NOCS), according to a study published online Sept. 26 in Diabetes, Obesity and Metabolism. Raffaele Marfella, M.D., Ph.D., from Università degli Studi della Campania in Italy, and colleagues compared the 12-month prognosis of individuals with...